Although the various standard neoadjuvant regimens for HER2-positive breast cancer from related breast cancer guidelines are widely used in clinical practice, the results of our study provide evidence on the feasibility and safety of the TKIs combined with anthracycline and cyclophosphamide as a new neoadjuvant therapy for HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.